Zentalis Pharmaceuticals (ZNTL) Competitors $1.37 -0.05 (-3.52%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.82%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. ERAS, SANA, ZVRA, ALT, SNDL, ORKA, KMDA, RVNC, TECX, and AUTLShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Erasca (ERAS), Sana Biotechnology (SANA), Zevra Therapeutics (ZVRA), Altimmune (ALT), SNDL (SNDL), Oruka Therapeutics (ORKA), Kamada (KMDA), Revance Therapeutics (RVNC), Tectonic Therapeutic (TECX), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Erasca Sana Biotechnology Zevra Therapeutics Altimmune SNDL Oruka Therapeutics Kamada Revance Therapeutics Tectonic Therapeutic Autolus Therapeutics Erasca (NASDAQ:ERAS) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Which has more risk and volatility, ERAS or ZNTL? Erasca has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Do insiders and institutionals believe in ERAS or ZNTL? 67.8% of Erasca shares are owned by institutional investors. 21.5% of Erasca shares are owned by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in ERAS or ZNTL? Zentalis Pharmaceuticals received 33 more outperform votes than Erasca when rated by MarketBeat users. However, 74.36% of users gave Erasca an outperform vote while only 62.00% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes2974.36% Underperform Votes1025.64% Zentalis PharmaceuticalsOutperform Votes6262.00% Underperform Votes3838.00% Which has higher earnings and valuation, ERAS or ZNTL? Erasca has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Erasca is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.74-1.93Zentalis Pharmaceuticals$67.43M1.46-$292.19M-$2.32-0.59 Does the media favor ERAS or ZNTL? In the previous week, Erasca had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 9 mentions for Erasca and 8 mentions for Zentalis Pharmaceuticals. Erasca's average media sentiment score of 1.41 beat Zentalis Pharmaceuticals' score of 1.17 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ERAS or ZNTL? Erasca presently has a consensus price target of $4.83, indicating a potential upside of 238.00%. Zentalis Pharmaceuticals has a consensus price target of $8.24, indicating a potential upside of 501.78%. Given Zentalis Pharmaceuticals' higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Is ERAS or ZNTL more profitable? Erasca's return on equity of -42.26% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Zentalis Pharmaceuticals N/A -43.91%-34.96% SummaryErasca beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.38M$6.81B$5.52B$7.84BDividend YieldN/A3.11%5.11%4.23%P/E Ratio-0.557.3322.4018.52Price / Sales1.46240.73399.74103.35Price / CashN/A65.8538.1834.62Price / Book0.226.396.744.24Net Income-$292.19M$142.94M$3.22B$248.05M7 Day Performance-6.80%4.50%4.33%5.03%1 Month Performance-24.31%-1.61%-0.82%1.69%1 Year Performance-88.00%-2.44%16.67%4.20% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.2939 of 5 stars$1.37-3.5%$8.24+501.8%-87.2%$98.38M$67.43M-0.55160Upcoming EarningsNews CoveragePositive NewsERASErasca3.204 of 5 stars$1.40+0.7%$4.83+245.2%-25.9%$396.57MN/A-1.69120News CoveragePositive NewsSANASana Biotechnology1.9232 of 5 stars$1.76-0.6%$10.80+513.6%-79.8%$396.04MN/A-1.26380Upcoming EarningsZVRAZevra Therapeutics2.7835 of 5 stars$7.20flat$22.29+209.5%+59.3%$393.69M$23.61M-3.6520Upcoming EarningsPositive NewsALTAltimmune2.5314 of 5 stars$5.06-0.2%$20.83+311.7%-30.3%$389.69M$20,000.00-3.2650News CoveragePositive NewsSNDLSNDL2.8628 of 5 stars$1.47-1.3%$3.63+146.6%-26.9%$386.28M$920.45M-4.74580Upcoming EarningsORKAOruka Therapeutics3.2599 of 5 stars$10.28+1.9%$39.86+287.7%N/A$384.89MN/A-1.64N/ANews CoverageKMDAKamada3.9897 of 5 stars$6.64-0.7%$14.67+120.9%+28.9%$381.67M$160.95M23.71360Upcoming EarningsShort Interest ↓RVNCRevance Therapeutics2.1091 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastTECXTectonic Therapeutic2.5618 of 5 stars$20.18-4.3%$72.40+258.8%N/A$376.62MN/A-3.43120Short Interest ↑Gap UpAUTLAutolus Therapeutics2.7017 of 5 stars$1.39+4.5%$9.32+570.5%-65.3%$369.87M$10.12M-1.15330News Coverage Related Companies and Tools Related Companies ERAS Competitors SANA Competitors ZVRA Competitors ALT Competitors SNDL Competitors ORKA Competitors KMDA Competitors RVNC Competitors TECX Competitors AUTL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZNTL Stock Free ZNTL Stock Alerts